Deflazacort and fluoximesterone in advanced, pretreated breast cancer.

Abstract

A very simple, low dose, orally administered regime (10 to 15 mg of fluoximesterone + 6 mg of deflazacort daily for periods of 1 to several months) resulting in mild-acceptable toxicity (essentially some weight gain) determined subjective improvement in 2/3 of 34 evaluable patients (out of 36 treated) and an objective measurable tumor reduction in 1/3, although most patients had been previously treated with chemotherapy and hormone treatment and proved primarily or secondarily refractory. The receptor status at the beginning of fluoximesterone+deflazacort treatment was not known, except in one negative-receptor patient, who responded to the combination after becoming resistant to tamoxifen (see photo). In some patients the condition of hormone refractoriness would suggest a no-treatment policy, but a trial with this regime is always convenient as it may improve both duration and quality of life.

• Authors: A Fornasiero, E Ferrazzi, S M Aversa, O Daniele, C Ghiotto, V C Sileni, P De Besi, M V Fiorentino
• Journal: Tumori (Tumori) Vol. 78 Issue 4 Pg. 266-9 (Aug 31 1992) ISSN: 0300-8916 [Print] United States
• PMID: 1466084 (Publication Type: Journal Article)

Chemical References

• Pregnenediones
• Fluoxymesterone
• deflazacort

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy)
• Female
• Fluoxymesterone (administration & dosage, adverse effects)
• Humans
• Middle Aged
• Pregnenediones (administration & dosage, adverse effects)